Evidence map›Paper›PMID 41140389›Full record

ArticleRespirology case reports2025

Neoadjuvant Selpercatinib for Stage IIIA Primary Pulmonary Adenocarcinoma With RET Fusion: A Case Report.

Zihan Cui, Yizhuo Hu, Jun Zhao, Chuanyong Mu, Chang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zihan CuiDepartment of Thoracic Surgery The First Affiliated Hospital of Soochow University, Medical College of Soochow University Suzhou China.ORCID https://orcid.org/0000-0002-3148-7865
Yizhuo HuDepartment of Thoracic Surgery The First Affiliated Hospital of Soochow University, Medical College of Soochow University Suzhou China.
Jun ZhaoDepartment of Thoracic Surgery The First Affiliated Hospital of Soochow University, Medical College of Soochow University Suzhou China.
Chuanyong MuDepartment of Respiratory and Critical Care Medicine The First Affiliated Hospital of Soochow University, Medical College of Soochow University Suzhou China.
Chang LiDepartment of Thoracic Surgery The First Affiliated Hospital of Soochow University, Medical College of Soochow University Suzhou China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selpercatinib represents the first targeted therapeutic agent approved for RET fusion-positive unresectable non-small cell lung cancers. This case report describes a patient with stage IIIA (cT2aN2M0) RET fusion-mutated adenocarcinoma of the left upper lobe. Following 9 months of selpercatinib therapy, the patient achieved clinical downstaging and subsequently underwent curative resection. Postoperative pathologic staging was IIA (ypT1bN1M0). Adjuvant therapy with selpercatinib was continued postoperatively. The patient remained recurrence-free on continued follow-up with 17 months since diagnosis and 8 months since surgery.

Indexed as

neoadjuvant therapyNSCLCselpercatinib

Identifiers

PMID41140389
PMCPMC12549053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.